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Abstract
Eukaryotes, protozoan, and helminth parasites make extensive use of protein kinases to control cellular functions,
suggesting that protein kinases may represent novel targets for the development of anti-parasitic drugs. Because of their
central role in intracellular signaling pathways, cyclic nucleotide–dependent kinases such as cAMP-dependent protein
kinase (PKA) represent promising new targets for the treatment of parasitic infections and neoplastic disorders. However,
the role of these kinases in schistosome biology has not been characterized and the genes encoding schistosome PKAs
have not been identified. Here we provide biochemical evidence for the presence of a PKA signaling pathway in adult
Schistosoma mansoni and show that PKA activity is required for parasite viability in vitro. We also provide the first full
description of a gene that encodes a PKA catalytic subunit in S. mansoni, named SmPKA-C. Finally we demonstrate,
through RNA interference, that SmPKA-C contributes to the PKA activity we detected biochemically and that inhibition of
SmPKA-C expression in adult schistosomes results in parasite death. Together our data show that SmPKA-C is a critically
important gene product and may represent an attractive therapeutic target for the treatment and control of
schistosomiasis.
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Introduction
Schistosomiasis, a disease caused by trematodes of the genus
Schistosoma, afflicts approximately 200 million people in tropical
and subtropical regions of the world and is responsible for
approximately 280,000 deaths annually in Sub-Saharan Africa
alone [1]. The schistosome life cycle is remarkably complex,
involving multiple life cycle stages that are morphologically and
physiologically adapted for survival within and transmission
between the molluscan and vertebrate hosts these parasites require
for life cycle completion. Within each host, evasion of host
defenses is balanced with requirements for host resources and
signals that are necessary for schistosome growth and develop-
ment. While specific examples have not been characterized at the
molecular level, there is considerable evidence for interactions
between schistosomes and host factors, such as hormones and
growth factors, which influence aspects of parasite biology such as
development and reproduction [2–5]. This intimate relationship,
where schistosomes exploit host factors to facilitate establishment
of infection while simultaneously evading host defenses, is
presumably a reflection of extensive host-parasite co-evolution
that has occurred since the emergence of the genus Schistosoma
some 12–19 million years ago [6].
Currently the anthelminthic praziquantel is the sole drug used for
treatment of schistosomiasis, due to its ability to kill the adult worms
ofallmedicallyimportantSchistosomaspecies [7].However, thereare
reasons to suspect that reliance on this single drug for all treatment
and control of schistosomiasis will not be sustainable in the long
term. First, praziquantel-tolerant strains of S. mansoni can be derived
in the laboratory by exposure to sub-curative doses of praziquantel
[8,9]. Second, evidence for decreased sensitivity to praziquantel has
been found following mass drug treatment efforts [10]. Thus the
potentialforpraziquantelresistance isrealand the increasingly wide
scale use of praziquantel, through programs such as the Schisto-
somiasis Control Initiative, highlight the necessity for the identifi-
cation of new chemotherapeutic targets in schistosomes [11] .
Protein kinases represent a potentially new class of therapeutic
targets for the treatment of parasitic diseases [12]. Through the
phosphorylation of substrate proteins, protein kinases play a central
role in the cellular signaling pathways of eukaryotic organisms and
are involved in biological processes as diverse as gene expression,
metabolism, apoptosis, and cellular proliferation [13]. The
unregulated activity of protein kinases has been implicated in the
pathogenesis of several human diseases, including cancer, autoim-
mune diseases and inflammation [14,15]. Consequently, the
development of protein kinase inhibitors as therapeutics for cancer
and other diseases has been actively pursued [16]. As eukaryotes,
protozoan and helminth parasites presumably also make extensive
use of protein kinases to control cellular functions, suggesting that
protein kinases may represent novel targets for the development of
anti-parasitic drugs [17,18]. Examples of promising protein kinase
targets in parasites include the cyclic guanosine monophosphate-
(cGMP-) dependent protein kinases (PKGs) of Toxoplasma [19],
Eimeria [20] and Plasmodium [21], and a Plasmodium cyclic adenosine
monophosphate- (cAMP-) dependent protein kinase (PKA) [22], as
inhibition of these kinases resulted in significant anti-parasitic effects
in vivo or in vitro [20,23]. Regulated by cyclic nucleotide second
messengers produced by purine nucleotide cyclases, cyclic nucleo-
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targets as, in addition to targeting the kinase domain directly, their
activity can also be manipulated by targeting the regulatory cyclic
nucleotide binding (CNB) domains with cyclic nucleotide analogs
[24]. Indeed, an experimental therapy for some cancers in which
PKA is implicated utilizes this latter approach and is now in clinical
trials [25]. A consistent difference between PKA and PKG across
highly divergent taxa is that in PKA, the regulatory and catalytic
activities are contained within separate gene products known as
PKA-R and PKA-C respectively, whereas in PKG the CNB sites
and catalytic domain are usually contained within the same
polypeptide. Thus the inactive conformation of PKA is a
heterotetramer of two PKA-R and two PKA-C subunits, while
PKG exists as a homodimer. Segregation of the catalytic and
regulatory functions of PKA into separate proteins provides an
opportunity for diversification in the function of PKA, as different
PKA-C and PKA-R isoforms can combine to produce holoenzymes
withdifferent functions[26]. Mammalian genomes contain as many
as three pka-c genes and four pka-r genes, allowing for a variety of
different holoenzymes to be formed [27].
While cyclic nucleotide-dependent kinases have been extensive-
ly characterized in a variety of eukaryotic organisms, including
several parasites, there is relatively little data available on the role
of these kinases in the biology of schistosomes. A study by
Matsuyama et al. showed that treatment of schistosome miracidia
with adenylyl cyclase and PKA inhibitors completely inhibited
miracidial locomotion in a dose-dependent manner, suggesting a
role for PKA in miracidial swimming [28]. In contrast, Kawamoto
et al. found that treatment of miracidia with adenylyl cyclase
agonists inhibited miracidium to mother sporocyst transformation,
while drugs that decreased cAMP levels triggered transformation
[29]. These studies suggest that cAMP and PKA play important
roles in the larval stages of the schistosome life cycle. However, no
studies have examined the role of PKA in adult schistosome
biology and full-length nucleotide sequences encoding schistosome
PKAs have not been identified. We hypothesized that PKA plays a
vital role in adult worms and that targeting PKA may represent a
novel approach to eliminating adult schistosomes from infected
mammalian hosts. In this report, we provide a biochemical
characterization and molecular identification of a S. mansoni PKA
(SmPKA). Furthermore, we show that the schistosome PKA is an
essential gene product for adult worms and as such represents an
attractive therapeutic target for the treatment and control of
schistosomiasis.
Materials and Methods
Ethics statement
All experiments involving mice were performed in accordance
with protocols approved by the USUHS Institutional Animal Care
and Use Committee.
Parasite materials
Biomphalaria glabrata snails infected with NMRI/Puerto Rican
strain of S. mansoni were supplied by Dr. Fred Lewis (Biomedical
Research Institute, Rockville, MD). Cercariae were obtained by
exposing infected snails to light for 2 h in 50 mL of filtered water.
Schistosomula were prepared by mechanical transformation of
cercariae according to published protocols [30]. Adult S. mansoni
were obtained from 6 week-infected C57BL/6 mice that were
infected with 150 cercariae using the tail immersion method [30].
Western blotting
Freshly isolated adult worms were homogenized in cell
extraction buffer (100 mM NaCl, 25 mM Tris pH 7.5) containing
a protease inhibitor cocktail (Sigma; 4-(2-aminoethyl) benzenesul-
fonyl fluoride hydrochloride (AEBSF; 1 mM), aprotinin (0.8 mM),
leupeptin (20 mM), bestatin (40 mM), pepstatin A (15 mM), and E-
64 (14 mM)). The resulting homogenate was incubated on ice for
30 min and centrifuged at 13,000 rpm for 20 min at 4uCt o
remove insoluble material. The protein concentration of the
resulting supernatant (Sm lysate) was determined using the Quick
Start Bradford Protein Assay. Western blots were performed using
the WesternBreeze Chemiluminescent Western Blot Immunode-
tection Kit (Invitrogen). Briefly, 7 mg of total protein from adult
worms, HT1080, and 293FT cells were used per sample. Reduced
samples were separated by SDS-PAGE on 12% Bis-Tris gels and
transferred onto polyvinyl difluoride (PVDF) membranes. After an
initial blocking step in 5% non-fat dried milk, 20 mM Tris pH 7.5,
membranes were incubated for 12 h with polyclonal anti-PKA C-
a antibody (Cell Signaling Technology) diluted 1:1000 and then
with alkaline phosphatase-conjugated goat anti-rabbit secondary
antibody (Invitrogen) for 2 h. Bound antibody was detected
according to manufacturer’s instructions using Kodak BioMax
Light Film.
Detection of PKA enzymatic activity
PKA activity was measured using a fluorescent peptide
substrate-based assay (Omnia Lysate Assay for PKA kit,
Biosource). Freshly isolated adult worms were used to prepare
Sm lysate, in the presence of protease and phosphatase inhibitor
cocktails (Phosphatase Inhibitor Cocktail 1(Sigma), containing
cantharidin, bromotetramisole and microcystin LR, diluted 1:100)
as described above. The protein concentration was determined
using the Quick Start Bradford Protein Assay and adjusted to a
final concentration of 0.2 mg/mL with additional extraction buffer.
Kinase reactions containing 1 mg total protein (equivalent to 5 mL
Sm lysate), 10 mM ATP, 15 mM PKA peptide substrate, 10 mM
DTT and a non-PKA inhibitor cocktail (64 mM PKC inhibitor
peptide, 10 mM GF109203X, 20 mM calmidazolium) in kinase
reaction buffer were assembled in opaque 96-well assay plates,
according to the manufacturer’s recommendations. Accumulation
of phosphorylated substrate was monitored during a 1 h
incubation at 30uC by recording fluorescent emissions at a
wavelength of 485 nm upon excitation at 360 nm, using a
Author Summary
Schistosomes are parasitic flatworms that inhabit the
circulatory system and are the cause of a debilitating and
insidious disease for millions of people worldwide. Like
other complex organisms, schistosomes and other para-
sitic worms regulate their cell biology through extensive
use of enzymes called protein kinases that phosphorylate
other proteins to alter their function. One such protein
kinase, cAMP-dependent protein kinase (PKA), has been
proposed as a therapeutic target for the treatment of
parasitic infections and cancer. Here we use biochemical
techniques to show that schistosome worms possess a
functional PKA pathway that is required for survival of the
parasites. We also identify a parasite gene that encodes a
functional PKA enzyme and show that silencing this gene
results in both significant loss of PKA activity in
schistosome worms and parasite death. These findings
suggest that the gene we have identified is critically
important to schistosomes and that its protein product
may represent a target for the development of much-
needed new drugs to treat schistosome infections.
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Fluorescence measurements were recorded every 30 s in relative
fluorescence units (RFUs). Kinase reactions containing 2 ng
recombinant human PKA-Ca catalytic subunit (Invitrogen) were
used as positive controls. PKA activity was plotted using
GraphPad Prism software version 4 (Graphpad Software, Inc.).
Symbols at each time point represent the means of three biological
replicates and experiments were performed at least twice.
PKA inhibitor assays
H-89 and protein kinase A inhibitor fragment 14–22 (PKI 14–22
amide) were purchased from Invitrogen. H-89 was dissolved in
dimethyl sulfoxide (DMSO) and PKI 14–22 amide was dissolved in
water. Kinase reactions were performed as described above in the
presence of H-89 and PKI 14–22 amide or appropriate vehicle
control at the following concentrations: 500, 100, and 10 mM. The
maximum concentration of DMSO in any reaction was less than 5%
and no differences in kinase activity were observed between controls
treated with water or DMSO. PKA activity in presence and absence
of inhibitor was determined as described in the previous section.
Adenylyl cyclase agonist and inhibitor assays
Forskolin and SQ22536 were purchased from Sigma and stock
solutions prepared in DMSO. To examine the effects of forskolin
and SQ22536 on PKA activity, triplicate groups of freshly isolated
adult worm pairs (10 pairs per group) were incubated for 2 h at
37uC in 24 well tissue culture plates containing Dulbecco’s
modified Eagle’s medium (DMEM) in the presence of 100 or
50 mM of forskolin, SQ22536 or DMSO alone. Then Sm lysate
was prepared from the treated worms and PKA activity was
measured as described above.
In vitro treatment of adult worms with PKA inhibitors
Effects of SmPKA inhibition in adult worms were assessed using
H-89 and PKI 14–22 at the following concentrations: 500, 250, 100,
50, 25, 10, and 1 mM. Individual adult worm pairs (6 pairs per
concentration) were placed in the wells of 24 well tissue culture plates
containing 1 mL total of DMEM (with 10% fetal bovine serum and
5% penicillin/streptomycin) and appropriate concentration of
inhibitor. Equal amounts of appropriate vehicle alone were added
to the wells containing control worms. Medium containing inhibitor
or vehicle was replaced daily. Worms were incubated at 37uCi n5 %
CO2 a n do b s e r v e de v e r y2 4hf o rap e r i o do f7d .W o r m sw e r e
considered to be dead when all evidence of motility, including gut
peristalsis, had ceased. Kaplan-Meier survival curves were generated
using GraphPad Prism software. Photomicrographs were obtained
using a Zeiss CL1500ECO dissecting microscope.
SmPKA-C cDNA cloning and sequence analysis
Total RNA was extracted from adult worms using the RNAzol B
Method (IsoTex Diagnostics, Inc.). 1 mg RNA was used to
synthesize cDNA using the iScript Select cDNA Synthesis Kit and
an oligo (dT)20primer(Bio-Rad).Thefull-length cDNA sequence of
SmPKA-C was obtained using the RNA ligase-mediated rapid
amplification of 59 and 39 cDNA ends (RACE) kit (Invitrogen) and
internal gene specific primers designed from the S. mansoni EST
Sm11052. RACE products of interest were purified using the
QIAquick Gel Extraction Kit (Qiagen), cloned into the pCR2.1-
TOPO vector (Invitrogen) and sequenced using the Big-Dye
Terminator cycle sequencing kit (Applied Biosystems). The
SmPKA-C cDNA sequence was compared to genomic sequences
available at the National Center for Biotechnology Information
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)andthe S.mansoni Genome
Project website (http://www.genedb.org/genedb/smansoni/blast.
jsp) blast servers. Vector NTI software (Invitrogen) was used to align
thenucleotideandaminoacid sequencesofSmPKA-CwithPKA-C
subunit sequences from other eukaryotic organisms. Phylip
(Phylogeny Inference Package) software [31] was used to construct
the phylogenetic tree using the protein parsimony method (http://
mobyle.pasteur.fr/cgi-bin/portal.py?form=protpars).
Detection of SmPKA-C gene expression in S. mansoni life
cycle stages
Total RNA was extracted and cDNA was synthesized from
male and female adult worms, schistosomula, and cercariae as
described above. Egg, miracidium, and sporocyst cDNA were
kindly provided by Dr. Conor Caffrey (Sandler Center for Basic
Research in Parasitic Diseases, San Francisco, CA). To detect
SmPKA-C expression, the following primers were used to amplify
a 900 bp fragment of the SmPKA-C cDNA (nucleotide positions
50–952): forward 59–GGTAATGCACAAGCTGCTAAA–3 and
reverse 59-CCAATCGGTTGTTGCAAACC-39. The S. mansoni
alpha tubulin cDNA (GenBank Accession No. S79195) was used
as a positive control and a 100 bp fragment (nucleotide positions
1711–1824) was amplified by PCR using the following primers:
forward 59-GGTTGACAACGAGGCCATTTATG-39 and re-
verse 59-TGTGTAGGTTGGACGCTCTATATCT-39. Ampli-
cons were visualized by agarose gel electrophoresis.
SmPKA-C gene silencing using RNAi
A 900 bp SmPKA-C cDNA fragment was generated by PCR
using the primers and cycling parameters described above and the
resulting amplicon was cloned into pCRII-TOPO vector (Invitro-
gen). Plasmid DNA was linearized using SacIo rXhoI and used as
template to transcribe ssRNA using T7 and Sp6 RNA polymerases
and the MEGAscript RNA transcription kit (Ambion) [32].
SmPKA-C dsRNA was generated and purified using the MEGA-
script RNAi kit (Ambion) according to the manufacturer’s
instructions. A non-schistosome control dsRNA was generated
from the pCR-II TOPO vector as described above. Integrity of the
final dsRNA products was assessed by agarose gel electrophoresis.
10 or 30 mg of SmPKA-C or control dsRNA, diluted in 100 mlo f
electroporation buffer (Ambion), were delivered to groups of 12
mixed-sex adult worms via electroporation as described previously
[33]. Adult worms, placed in 4 mm cuvettes, were pulsed at room
temperature with a single 20 ms square wave pulse at 125 V using
the GenePulser Xcell Electroporation system (Bio-Rad). Adult
worms were immediately transferred to pre-warmed DMEM (10%
FBS and 5% penicillin/streptomycin) and maintained at 37uC. To
assess the efficacy of SmPKA-C RNA knockdown, RNA was
extracted after 3 d and transcript levels assessed by PCR as
described above, except that primers which hybridize outside the
targeted region were used (forward 59-CGCGTAATATCACTT-
GAGAGTCAAAATAG-39 and reverse 59-AAATTCACTAAA-
TTCTTTTGCACATTTCTCTGTTGTAGCAATACG-39,t o
amplify a fragment corresponding to nucleotide positions 18–
1096), and the accumulation of PCR product was monitored in
real time by detection of SYBR Green fluorescence, using a M.J.
Research Chromo4 PCR cycler (Bio-Rad). Relative SmPKA-C
RNA levels were calculated using the 2
2DDCt method [34] and S.
mansoni alpha tubulin RNA as the control transcript. Data are
representative of two independent experiments.
Statistical analyses
The statistical significance of differences between treated and
control groups in activity assays was calculated using one-way
Schistosome Protein Kinase A
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differences between Kaplan-Meier survival curves was calculated
using the logrank test. P values#0.05 were considered statistically
significant. Student’s T test with Welch’s correction was used to
test the significance of differences in expression levels detected by
real-time PCR. GraphPad Prism software was used for all
statistical analyses.
Results
Detection of PKA protein expression and PKA enzymatic
activity in adult S. mansoni
To detect putative PKA-C subunit homologues in adult S.
mansoni protein lysate (Sm lysate), western blot analysis using a
polyclonal antibody generated against a conserved epitope of the
C-terminus of human PKA-Ca subunit was conducted (GenBank
Accession No. P17612). A band of 40 kDa was detected in Sm
lysate, which was similar in molecular weight to the human PKA-
Ca detected in the two human cell lines (Fig. 1A).
We next sought to determine if protein extracts from adult S.
mansoni had measurable PKA activity. Using a fluorescent peptide
substrate-based assay, a putative PKA activity was detected in
adult Sm lysate, as determined by the accumulation of a
fluorescent, phosphorylated peptide reaction product (Fig. 1B).
While reaction product accumulated more slowly in the Sm lysate
reaction than in a positive control reaction containing recombi-
nant human PKA-Ca (hereafter referred to as control PKA),
similar total amounts of product accumulated in both reactions by
the end of the assay.
While the peptide substrate used in the kinase activity contains a
specific PKA target sequence, other protein kinases such as protein
kinase C (PKC) and calmodulin-dependent protein kinases
(CDPKs) share similar substrate specificity to PKA [35]. For this
reason, a kinase inhibitor cocktail that inhibits PKC and CDPK
was included in all assays to eliminate non-PKA mediated
phosphorylation. To further confirm that the kinase activity
detected in Fig. 1B was attributable to a PKA enzyme, adult Sm
lysate was treated with inhibitors that target PKA-C subunits, H-
89 and PKI 14–22 amide, and the resulting activity was compared
to PKA activity in untreated control lysate. The PKA activity of
adult Sm lysate and control PKA was completely inhibited by
10 mM H-89 (P,0.0001) (Figs. 1C and 1D), an ATP-competitive
Figure 1. Detection of a putative schistosome PKA in parasite lysates. A, Western blotting of lysates from adult S. mansoni (Sm lysate) and
two human cell lines (293FT, HT1080) using a polyclonal antibody specific for the human PKA-Ca subunit revealed the presence of a putative PKA-C
subunit of the expected molecular weight of 40 kDa in the schistosome lysate. B, Putative PKA activity is detectable in lysate of adult S. mansoni
worms using a fluorescence-based kinase assay. m, Sm lysate,N recombinant human PKA-Ca. C–F, Kinase activity was measured in kinase reactions
containing Sm lysate (C and E) and recombinant human PKA-Ca (D and F) and the PKA inhibitors H-89 (C and D) and PKI 14–22 (E and F). m, inhibitor-
treated;N, no inhibitor. B–F, each time point represents the mean of three biological replicates.
doi:10.1371/journal.pntd.0000505.g001
Schistosome Protein Kinase A
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[36]. Identical results were obtained with 100 and 500 mM H-89
(data not shown). Similar to treatment with H-89, 10 mM PKI 14–
22 amide also significantly inhibited the PKA activity of Sm lysate
and the control PKA (P,0.0001) (Figs. 1E and 1F). PKI 14–22
amide is a highly specific inhibitor of PKA as it contains a
pseudosubstrate site which facilitates high affinity binding to the
substrate binding site of PKA-C subunits, preventing docking of
the substrate [37,38].
Modulation of parasite PKA activity through
manipulation of cAMP
Since cAMP binding to PKA-R subunits is required for PKA-C
release and activation, we hypothesized that if the kinase activity
we detected in Sm lysate was attributable to a PKA, its activity
would be sensitive to alterations in the availability of cAMP for R
subunit binding. To test this hypothesis, we tested whether the
schistosome PKA activity was sensitive to manipulation of
endogenous adenylyl cyclase activity [39]. The adenylyl cyclase
inhibitor, SQ22536 [40], and adenylyl cyclase agonist, forskolin
[41], were each used to either inhibit or activate endogenous
adenylyl cyclase activity, respectively. In order to maintain the
integrity of intracellular signaling pathways in these experiments,
intact adult worms were treated with inhibitor or agonist rather
than Sm lysate, as cellular structure is lost during preparation of
the parasite lysate. 100 mM SQ22536 significantly decreased PKA
activity in treated adult S. mansoni worms when compared to the
untreated controls (P,0.0001) (Fig. 2A), presumably by inhibiting
cAMP production and preventing the disassociation of PKA-C
subunits from the holoenzyme. In contrast to SQ22536, 100 mM
forskolin significantly increased PKA activity in treated adult
worms as compared to the untreated controls (P,0.0001) (Fig. 2C).
Similar activation and inhibition were seen with 50 mMo f
forskolin and SQ22536, respectively (data not shown). As
expected, the activity of the recombinant control PKA preparation
was not affected by SQ22536 or forskolin, as this preparation does
not contain adenylyl cyclase or PKA-R subunits (Figs. 2B and 2D).
Taken together, these data further support the conclusion that
the kinase activity we detected in adult S. mansoni extracts is
attributable to a PKA enzyme, as this activity can be inhibited and
activated using inhibitors and agonists of adenylyl cyclase.
Furthermore, our data suggest that S. mansoni possesses a
functional cAMP signaling pathway, containing adenylyl cyclase
and both regulatory and catalytic PKA subunits.
PKA activity is required for the viability of adult S.
mansoni worms in vitro
To test whether the schistosome PKA activity plays a significant
role in parasite biology, we next analyzed the effect of the
inhibitors H-89 and PKI 14–22 amide on adult worms in vitro.
Treating worms with H-89 at concentrations of 50–500 mM
resulted in 100% mortality within 24 h (Fig. 3A). Incubation of
worms with H-89 at 25 mM resulted in 75% mortality by Day 3
and 100% by Day 4 (Fig. 3A). Treatment with H-89 at 10 mM
resulted in 100% mortality by Day 5 (Fig. 3A). Prior to parasite
death, exposure to H-89 caused a cessation in egg production and
resulted in dissociation of males and females (Fig. 3B), effects that
were evident at H-89 concentrations as low as 1 mM concentration
(data not shown), despite the lack of a killing effect (Fig. 3A).
Similarly, incubation with 500 and 250 mM of PKI 14–22 amide
resulted in 100% worm mortality within 24 h of exposure (Fig. 3C),
while at 100 mM some worms survived until Day 3 (Fig. 3C).
Figure 2. Schistosome PKA activity is sensitive to adenylyl cyclase modulation. Kinase activity was measured in kinase reactions containing
Sm lysate from adult worm pairs (A and C) that were previously treated with SQ22536 (A) or forskolin (C). Treatment groups contained 10 worm pairs
(20 worms total) each and were performed in triplicate. Kinase reactions containing recombinant human PKA-Ca (B and D) were treated directly with
SQ22536 (B) or forskolin (D). m, inhibitor-treated;N, no inhibitor. Data are representative of two independent experiments.
doi:10.1371/journal.pntd.0000505.g002
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100% survival (Fig. 3C). As with H-89, PKI 14–22 amide caused
cessation of egg production and unpairing prior to parasite death
(Fig. 3D). These data show that loss of PKA activity by inhibition
of PKA-C subunits is lethal for adult S. mansoni in vitro and suggest
that the schistosome PKA is essential for maintaining parasite
viability.
Identification of a SmPKA-C cDNA and its expression in S.
mansoni life cycle stages
To identify cDNA sequences that might encode for PKA-C
subunits in S. mansoni, BLASTX searches of the S. mansoni genome
database (http://www.genedb.org/genedb/smansoni/blast.jsp)
were performed using PKA-C protein sequences from other
organisms. A 622 bp EST (Sm11052) with significant similarity to
other PKA-C subunits was identified. Sm11052 contained an
incomplete open reading frame (ORF) that encoded for the N-
terminal portion of a protein kinase domain, as determined by the
presence of a complete ATP-binding site (corresponding to the
consensus motif Gly–x–Gly–x–x - Gly–x–Val) and a serine/
threonine kinase active site containing the motif Arg - Asp–Asp–
Leu–Lys–x–x–Asn [13]. The complete sequence of the cDNA was
obtained by 59 and 39 RACE using gene-specific primers that
annealed within the Sm11052 sequence and the entire cDNA was
then amplified from adult S. mansoni cDNA. The full-length cDNA
is 1899 bp long and contains a complete ORF of 1053 bp,
encoding for a protein of 350 amino acids in length and with a
predicted molecular mass of 40.4 kDa (GenBank Accession
No. GQ168377). The ORF encoded for a putative protein kinase,
with intact N and C-termini and a C-terminal kinase domain that
contained all 12 conserved subdomains characteristic of protein
kinase domains [13]. BLAST comparison of the amino acid
sequence with the non-redundant protein sequence database at
NCBI showed that the putative S. mansoni PKA-C (SmPKA-C)
protein shared 70% similarity with PKA-C subunits from other
eukaryotic organisms (Caenorhabditis elegans, Drosophila melanogaster,
Mus musculus, and Homo sapiens) (Fig. 4A) and was most similar to
the PKA-C subunit from Aplysia californica (Fig. 4B). The estimated
molecular mass of SmPKA-C protein was also similar to that of
other PKA-C proteins and approximately matched the apparent
mass of the band detected in S. mansoni extracts by western blot
using anti-human PKA-C antibodies in Fig. 1A. Qualitative
analysis of SmPKA-C expression in various life cycle stages by
reverse transcriptase PCR revealed that SmPKA-C transcript was
detectable in all S. mansoni life cycle stages tested (egg, miracidium,
sporocyst, cercaria, schistosomulum, adult male and female;
Fig. 4C).
The ORF of SmPKA-C was then compared using BLAST
analysis to the S. mansoni genome database to identify other
putative PKA-C subunit sequences encoded by the S. mansoni
genome. One sequence, Smp_152330, was identified that was
95% identical to the SmPKA-C nucleotide sequence. PCR
analysis showed that the 39end of the predicted database sequence
was incorrect and, using 39 SmPKA-C gene-specific primers, we
were able to amplify the correct cDNA sequence of Smp_152330
from adult S. mansoni cDNA. Translation of the Smp_152330
nucleotide sequence showed it contained 18 more amino acids at
the N-terminus than the SmPKA-C protein, but the remainder of
both the nucleotide and amino acid sequences were identical
(Fig. 4A and data not shown), suggesting that the corrected
Figure 3. PKA activity is essential for adult S. mansoni viability in vitro. Adult S. mansoni worm pairs were maintained in medium containing
varying concentrations of H-89 (A and B) or PKI 14–22 amide (C and D). Survival in the presence of each inhibitor was plotted against time (A and C).
For H-89, concentrations of inhibitor are as follows: 0 and 1 mM(N); 10 mM( ¤); 25 mM( &); 50, 100, 250, and 500 mM( .). For PKI 14–22 amide
concentrations of inhibitor are as follows: 0, 1, 10, 25, and 50 mM(N); 100 mM( ¤); 250 and 500 mM( &). Treatment groups containing 6 worm pairs
each (12 worms total) were used for each concentration. B and D, micrographs of representative worm pairs incubated in the presence of 100 mMH -
89 (B) or100 mM PKI 14–22 amide (D). Scale bars=1 mm. e, parasite eggs. Data are representative of three independent experiments.
doi:10.1371/journal.pntd.0000505.g003
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www.plosntds.org 6 August 2009 | Volume 3 | Issue 8 | e505Figure 4. Identification of SmPKA-C as a PKA-C subunit from S. mansoni. A, Amino acid alignment of both SmPKA-C and putative splice
variant peptide sequences with PKA-C sequences from Caenorhabditis elegans (Cekin-1; NP_493605), Drosophila melanogaster (DmPKA; NP_476977),
Mus musculus (MmPKAa; P05132) and Homo sapiens (HsPKAa; P17612). B, Phylogenetic analysis comparing both SmPKA-C amino acid sequences to
the following PKA-C sequences from other organisms: Homo sapiens PKA-Ca (HsPKAa; P17612), H. sapiens PKA-Cb (HsPKAb; P22694), H. sapiens PKA-
Cc (HsPKAg; P22612), Mus musculus PKA-Ca (MmPKAa; P05132), M. musculus PKA-Cb (MmPKAb; P68181), Rattus norvegicus PKA-Ca (RnPKAa; P27791),
R. norvegicus PKA-Cb (RnPKAb; P68182), D. melanogaster (DmPKA; NP_476977), Aplysia californica (AcPKA; CAA45014), and Acyrthosiphon pisum
(ApPKA; XP_001946114). C, SmPKA-C transcript is expressed in cDNA of all the life cycle stages of S. mansoni. 1, egg, 2, miracidium, 3, sporocyst, 4,
cercaria, 5, schistosomulum, 6, adult female, 7, adult male.
doi:10.1371/journal.pntd.0000505.g004
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SmPKA-C.
Silencing of SmPKA-C expression by RNAi
To determine the effect of silencing SmPKA-C expression in S.
mansoni, adult worms were treated via electroporation with 30 mg
of SmPKA-C dsRNA or control dsRNA. We observed 75%
mortality of adult worms treated with 30 mg of SmPKA-C dsRNA
by Day 3, while all control dsRNA-treated parasites survived
(Fig. 5A). To reduce parasite mortality and provide more surviving
worms for subsequent analysis, the amounts of dsRNA were
reduced in subsequent experiments. Treatment with 10 mgo f
SmPKA-C dsRNA resulted in 92% survival of worms, while
treatment with 10 mg of control dsRNA again resulted in 100%
survival to Day 3 (data not shown). Real-time PCR analysis of
SmPKA-C transcript levels in surviving worms on day 3 post-
electroporation revealed a significant reduction of SmPKA-C
mRNA in SmPKA-C dsRNA-treated worms to approximately 1%
of the levels detected in control dsRNA-treated worms (P=0.0034)
(Fig. 5B).
To determine whether SmPKA-C contributes to the PKA
activity detected in Sm lysate, PKA activity was measured in
lysates prepared from worms that were treated with 10 mg
SmPKA dsRNA or control dsRNA 7 days previously. Worms
were treated with 100 mM forskolin for 2 hours prior to lysate
preparation in order to reactivate PKA activity. SmPKA activity
was significantly reduced in SmPKA-C dsRNA treated worms as
compared to the control dsRNA treated worms (P,0.05) (Fig. 5C).
Discussion
In this study, we provide the first direct evidence for the
expression of an active PKA in adult S. mansoni worms. First,
antibodies to a highly conserved motif from the PKA-C kinase
domain of other organisms reacted with a protein of the expected
size for a PKA-C subunit in protein extracts from adult worms.
Second, a protein kinase assay utilizing a peptide substrate that is
preferentially phosphorylated by PKAs demonstrated significant
PKA kinase activity in adult worm lysates. Third, the activity of
the putative PKA was sensitive to known inhibitors of PKA-C
kinase activity, providing further evidence that a PKA-C protein
was responsible for the activity we detected in parasite extracts.
Finally, exposure of intact parasites to an adenylyl cyclase inhibitor
and agonist either decreased or increased, respectively, the PKA
activity, demonstrating that the putative parasite PKA exhibits the
expected sensitivity to modulation of cAMP levels. Taken together,
these data support the conclusion that an active PKA is expressed
in adult S. mansoni, and that adult schistosomes also express
regulatory proteins that control PKA activation by cAMP, such as
adenylyl cyclase and PKA regulatory subunits.
We are aware of one other report which demonstrated that
targeting protein kinases in adult schistosomes can be detri-
mental to the parasites. In this report, the authors demonstrated
that, while exposure of adult S. mansoni worms to the broad
spectrum tyrosine kinase inhibitor herbimycin A in vitro was not
lethal to schistosome worms, parasite egg production was
significantly inhibited in a dose-dependent manner [42]. Here
we demonstrate that exposure of intact adult worms to
inhibitors of PKA kinase activity is lethal to the parasites,
suggesting that, in contrast to herbimycin-sensitive tyrosine
kinases, the schistosome PKA is critically important for
viability. H-89 in particular killed schistosomes rapidly at low
concentrations in vitro. However, while H-89 is considered a
specific inhibitor of PKA and its IC50 for PKA is in the low
Figure 5. SmPKA-C encodes for an essential kinase activity. A,
Electroporation of adult worms with 30 mg of SmPKA-C dsRNA (&)
resulted in 75% mortality while worms treated with control dsRNA (N)
exhibited 100% survival. B, Three days after electroporation, SmPKA-C
transcript levels were decreased in worms electroporated with 10 mgo f
SmPKA-C dsRNA, while transcript levels were unaffected in control
dsRNA-treated worms, as determined by real-time PCR. C, 7 days after
electroporation, SmPKA-C dsRNA-treated (N) and control dsRNA-
treated worms (m) were incubated for 2 h in 100 mM forskolin. PKA
activity was significantly decreased after electroporation with 10 mg
SmPKA-C dsRNA compared to control dsRNA-treated worms.
doi:10.1371/journal.pntd.0000505.g005
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kinases. For example, previous studies showed that H-89 also
inhibited ribosomal protein S6 kinase 1 (S6K1) and mitogen-
and stress-activated protein kinase (MSK1) at lower concentra-
tions than PKA [36,43]. Since these two kinases play a major
role in eukaryotic cell biology, the lethality observed on treating
adult worms with H-89 may not be due to PKA inhibition alone,
but rather the result of inhibition of several other kinases in
addition to PKA. However PKI 14–22 amide, a highly specific
inhibitor of PKA-C subunits that does not affect other protein
kinases [37], also caused parasite death, albeit at higher
concentrations than H-89, supporting the conclusion that
PKA activity is important for maintaining parasite viability. A
possible explanation for the difference in parasite killing we
observed with these two inhibitors is that PKI 14–22 amide is a
peptide, which would not be expected to penetrate the treated
p a r a s i t e sa sw e l la sH - 8 9 .A l t e r n a t ively, inhibition of additional
kinases by H-89 may enhance its toxicity for schistosome
worms.
Partial coding sequences for putative PKA-C genes have been
generated by the S. mansoni genome project, but no full-length
sequences for a schistosome PKA-C have been identified. Here we
report the isolation of a full-length cDNA encoding for a S. mansoni
PKA-C subunit we named SmPKA-C. Expression of this
transcript was detected in all life cycle stages we examined,
including adults, suggesting this cDNA may encode the PKA
activity we detected in adult worm extracts. Subsequent targeting
of the SmPKA-C transcript in adult schistosomes using RNAi was
lethal for the parasites, demonstrating that this gene is essential for
parasite viability, at least in vitro, and providing further support for
the conclusion that the parasite death we observed with the
inhibitors H-89 and PKI 14–22 amide were the result of PKA
inhibition. Consistent with this conclusion, RNAi inhibition of
SmPKA expression resulted in significant loss of PKA activity in
parasite lysates, confirming that at least a portion of the PKA
activity in adult worms is encoded by this transcript. Interestingly,
not all PKA activity was ablated by RNAi of SmPKA, despite
significant knock-down of transcript levels to approximately 1% of
the levels observed in control worms, raising the possibility that
other PKA isoforms are expressed by adult worms. Alternative
splicing in the N-termini of PKA-C subunits has been observed in
mammalian species and in invertebrates, such as C. elegans [44,45],
and our RACE experiments suggest that alternative splicing results
in the expression of at least two SmPKA-C isoforms in adult
schistosomes. However, the remaining activity cannot be attribut-
ed to either of these splice variants, as the two transcripts share the
sequence targeted by the dsRNA fragment we used for RNAi.
These observations suggest that S. mansoni expresses other PKA
isoforms, perhaps encoded by additional PKA genes or generated
by additional, less conservative alternative splicing, and argue that
a search for additional PKA-encoding sequences in S. mansoni
mRNA and genomic DNA is warranted. Alternatively, the
remaining PKA activity detected in RNAi-treated worms may
be due to residual SmPKA-C expression, as ablation of SmPKA-C
transcript was not absolute (Fig. 5B). Interestingly we were
unable,to amplify full-length cDNAs from adult worms that
correspond to other putative PKA genes that have been predicted
from sequences of S. mansoni genomic DNA (Smp_080770,
Smp_047150.2/1), suggesting that these genes are not expressed
in adult schistosomes or that the predicted coding sequences are
incorrect. Other putative S. mansoni PKA sequences (Smp_147450
and Smp_194610) appear to lack a functional kinase domain or
are missing amino acid residues that are critical for PKA function.
Thus the extent to which adult schistosomes express multiple PKA
isoforms remains unclear. However, as RNAi knockdown of
SmPKA-C resulted in parasite death, we conclude that SmPKA-C
is a critically important protein and propose that SmPKA may be
an attractive target for the development new schistosomicidal
therapeutics.
Tight regulation of PKA activity by PKA-R subunits provides
additional opportunities for pharmacological manipulation of
PKA, beyond targeting the PKA-C subunit directly with kinase
inhibitors. To date, there are no published reports that identify or
characterize PKA-R subunits in schistosomes, but the cDNA
sequence of a putative PKA-R subunit from S. mansoni was recently
released by the S. mansoni genome project (GenBank accession
no. CAY17207) and others may await identification. In other
organisms, variation in CBD sequences amongst PKA-R isoforms
results in differential affinity for cAMP and for cAMP analogs that
either induce or inhibit holoenzyme dissociation and activation of
the PKA-C subunits [46,47]. Thus there is considerable potential
for pharmacological manipulation of PKA activity using cAMP
analogs. One such analog, 8-Cl-cAMP, has been shown to be a
potent growth inhibitor in numerous human cancer cell lines and
has completed phase I clinical trials for the treatment of some
cancers [25]. Identification and analysis of schistosome PKA-R
subunits may identify opportunities for the pharmacological
targeting of parasite PKA in a similar manner to that now in
development for cancer treatment. These observations highlight
the obvious parallels between the treatment of cancer and parasitic
infections, which both involve the targeting of eukaryotic cells, and
suggest that novel approaches to cancer chemotherapy may
provide new leads for the development of much needed anti-
parasitic drugs.
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